{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:25:36Z","timestamp":1791109536023,"version":"4.1.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5611,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.nurt.2007.12.001","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T09:42:40Z","timestamp":1207129360000},"page":"164-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Current Status of Symptomatic Medical Therapy in Parkinson\u2019s Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Stewart A.","family":"Factor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2007.12.001_bib1","series-title":"Handbook of Parkinson\u2019s disease","first-page":"309","article-title":"Levodopa","author":"Factor","year":"2007"},{"key":"10.1016\/j.nurt.2007.12.001_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00726-001-0111-9","article-title":"L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent","volume":"23","author":"Hornykiewicz","year":"2002","journal-title":"Amino Acids"},{"key":"10.1016\/j.nurt.2007.12.001_bib3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/mds.10115","article-title":"Dopamine miracle: from brain homogenate to dopamine replacement","volume":"17","author":"Hornykiewicz","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1212\/WNL.50.4.858","article-title":"Levodopa: is toxicity a myth?","volume":"50","author":"Agid","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: a consensus meeting","volume":"14","author":"Agid","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.12.001_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of parkinsonism: chronic treatment with L-DOPA","volume":"280","author":"Cotzias","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.12.001_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","article-title":"Treatment of parkinsonism with levodopa","volume":"21","author":"Yahr","year":"1969","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib9","first-page":"1","article-title":"The history of drugs for the treatment of Parkinson\u2019s disease","volume":"38","author":"Kapp","year":"1992","journal-title":"J Neural Transm"},{"key":"10.1016\/j.nurt.2007.12.001_bib10","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1212\/WNL.29.12.1584","article-title":"Levodopa with benserazide or carbidopa in Parkinson disease","volume":"29","author":"Rinne","year":"1979","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00312459","article-title":"Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson\u2019s disease: a controlled clinical trial","volume":"211","author":"Rinne","year":"1975","journal-title":"J Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib12","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.38.7.1143","article-title":"Controlled-release carbidopa\/levodopa (CR4-Sinemet) in Parkinson\u2019s disease patients with and without motor fluctuations","volume":"38","author":"Goetz","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.870040403","article-title":"Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations","volume":"4","author":"Jankovic","year":"1989","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/jnnp.52.1.83","article-title":"Efficacy of Sinemet CR4 in subgroups of patients with Parkinson\u2019s disease","volume":"52","author":"Factor","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2007.12.001_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11940-001-0011-z","article-title":"Parkinson\u2019s Disease: initial treatment with levodopa or dopamine agonists","volume":"3","author":"Factor","year":"2001","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mds.870020201","article-title":"Young onset Parkinson\u2019s disease","volume":"2","author":"Quinn","year":"1987","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneur.63.2.205","article-title":"Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976\u20131990","volume":"63","author":"Van Gerpen","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib19","first-page":"2498","article-title":"Parkinson Study Group","volume":"351","author":"Fahn","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.nurt.2007.12.001_bib20","first-page":"iv37","article-title":"Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson\u2019s disease?","volume":"252","author":"Fahn","year":"2005","journal-title":"J Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib21","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.12.001_bib22","first-page":"1044","article-title":"Parkinson Study Group","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib23","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.nurt.2007.12.001_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson\u2019s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1353-8020(03)00040-3","article-title":"Malignant melanoma and levodopa in Parkinson\u2019s disease: causality or coincidence?","volume":"9","author":"Fiala","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjc.6602279","article-title":"Atypical cancer pattern in patients with Parkinson\u2019s disease","volume":"92","author":"Olsen","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nurt.2007.12.001_bib27","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/mds.21397","article-title":"Treatment with levodopa and risk for malignant melanoma","volume":"22","author":"Olsen","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib28","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.WNL.0000137886.74175.5A","article-title":"Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?","volume":"63","author":"Postuma","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib29","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1001\/jama.288.16.2023","article-title":"MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis","volume":"288","author":"Klerk","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.nurt.2007.12.001_bib30","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1212\/WNL.59.4.529","article-title":"Homocysteine, MTHFR 677C-->T polymorphism, and risk of ischemic stroke: results of a meta-analysis","volume":"59","author":"Kelly","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib31","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma homocysteine as a risk factor for dementia and Alzheimer\u2019s disease","volume":"346","author":"Seshadri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.12.001_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0404.2003.00135.x","article-title":"Levodopa-induced hyperhomocysteinaemia in Parkinson\u2019s disease","volume":"108","author":"Yasui","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nurt.2007.12.001_bib33","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/mds.20253","article-title":"Modest increase in plasma homocysteine follows levodopa initiation in Parkinson\u2019s disease","volume":"19","author":"O\u2019Suilleabhain","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","article-title":"Tolcapone decreases plasma levels of S-adenosyl-l-homocysteine and homocysteine in treated Parkinson\u2019s disease patients","volume":"62","author":"Muller","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.01.007","article-title":"Reduced plasma homocysteine levels in levodopa\/entacapone treated Parkinson patients","volume":"11","author":"Valkovic","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jocn.2004.09.012","article-title":"Endothelial function markers in parkinsonian patients with hyperhomocysteinemia","volume":"12","author":"Bostantjopoulou","year":"2005","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.nurt.2007.12.001_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0025-7125(05)70112-7","article-title":"Dopamine agonists","volume":"83","author":"Factor","year":"1999","journal-title":"Med Clin North Am"},{"issue":"1 Suppl 1","key":"10.1016\/j.nurt.2007.12.001_bib38","first-page":"S34","article-title":"The role of dopamine agonists in early Parkinson\u2019s disease","volume":"49","author":"Watts","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib39","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/bmj.4.5942.442","article-title":"Bromocriptine in parkinsonism","volume":"4","author":"Calne","year":"1974","journal-title":"Br Med J"},{"key":"10.1016\/j.nurt.2007.12.001_bib40","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib41","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","article-title":"Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson\u2019s disease","volume":"6","author":"Antonini","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.12.001_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-2999(96)00454-2","article-title":"Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists","volume":"312","author":"Piercey","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0014-2999(92)90024-X","article-title":"Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist","volume":"215","author":"Mierau","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib45","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.161.3.564","article-title":"Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression","volume":"161","author":"Goldberg","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.nurt.2007.12.001_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1034\/j.1399-5618.2002.01171.x","article-title":"Pramipexole in treatment-resistant depression: a 16-week naturalistic study","volume":"4","author":"Lattanzi","year":"2002","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib47","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, fluoxetine, and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depress Anxiety"},{"issue":"Suppl 1","key":"10.1016\/j.nurt.2007.12.001_bib48","first-page":"S58","article-title":"Pharmacologic profile of ropinirole: a nonergoline dopamine agonist","volume":"49","author":"Tulloch","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib49","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2125.1998.t01-1-00704.x","article-title":"Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients","volume":"45","author":"Brefel","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib50","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","article-title":"Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study","volume":"68","author":"LeWitt","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib51","series-title":"Parkinson\u2019s disease: diagnosis and clinical management","first-page":"515","article-title":"Dopamine agonists","author":"Nisipeanu","year":"2008"},{"key":"10.1016\/j.nurt.2007.12.001_bib52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.wnf.0000162228.00154.ba","article-title":"Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease","volume":"28","author":"Guldenpfennig","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib53","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","article-title":"A controlled trial of rotigotine monotherapy in early Parkinson\u2019s disease","volume":"60","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib54","first-page":"251","article-title":"Apomorphine in Parkinson\u2019s disease","volume":"56","author":"Schwab","year":"1951","journal-title":"Trans Am Neurol Assoc"},{"issue":"Suppl 4","key":"10.1016\/j.nurt.2007.12.001_bib55","first-page":"S8","article-title":"Subcutaneously administered apomorphine: pharmacokinetics and metabolism","volume":"62","author":"LeWitt","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib56","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1212\/WNL.49.3.724","article-title":"Pramipexole Study Group","volume":"49","author":"Shannon","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1997.03550020057038","article-title":"Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study","volume":"278","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.nurt.2007.12.001_bib58","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole Study Group","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib59","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/archneur.55.9.1211","article-title":"Ropinirole Study Group","volume":"55","author":"Sethi","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib60","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease [Erratum in: Neurology 2007;69:617; Neurology 2007;69:2187]","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib61","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.21741","article-title":"Rotigotine transdermal patch in early Parkinson\u2019s disease: a randomized, double-blind, controlled study versus placebo and ropinirole","volume":"22","author":"Giladi","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib62","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","article-title":"Clinical evaluation of pramipexole in advanced Parkinson\u2019s disease: results of a double-blind, placebo-controlled, parallel-group study","volume":"49","author":"Lieberman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib63","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.49.4.1060","article-title":"International Pramipexole\u2013Bromocriptine Study Group","volume":"49","author":"Guttman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib64","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","article-title":"Ropinirole Study Group","volume":"51","author":"Lieberman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib65","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"SP 515 Investigators","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurol"},{"issue":"Suppl 4","key":"10.1016\/j.nurt.2007.12.001_bib66","first-page":"S12","article-title":"Literature review: intermittent subcutaneous apomorphine therapy in Parkinson\u2019s disease","volume":"62","author":"Factor","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib67","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","article-title":"A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events","volume":"58","author":"Dewey","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.parkreldis.2006.06.012","article-title":"Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson\u2019s disease","volume":"13","author":"Pfeiffer","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib69","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/mds.870050404","article-title":"Sleep disorders and sleep effect in Parkinson\u2019s disease","volume":"5","author":"Factor","year":"1990","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib70","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","article-title":"Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole","volume":"52","author":"Frucht","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib71","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0140-6736(00)02118-8","article-title":"Sleep attacks (sleep episodes) with pergolide","volume":"355","author":"Shapira","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.nurt.2007.12.001_bib72","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/1531-8257(200003)15:2<212::AID-MDS1002>3.0.CO;2-6","article-title":"Waking up to sleep episodes in Parkinson\u2019s disease","volume":"15","author":"Olanow","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib73","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/1531-8257(200007)15:4<658::AID-MDS1009>3.0.CO;2-N","article-title":"Pramipexole-induced somnolence and episodes of daytime sleep","volume":"15","author":"Hauser","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib74","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mds.1083","article-title":"Sudden daytime sleep onset in Parkinson\u2019s disease: polysomnographic recordings","volume":"16","author":"Tracik","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib75","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2869.2000.00201.x","article-title":"Daytime sleepiness in Parkinson\u2019s disease","volume":"9","author":"Rye","year":"2000","journal-title":"J Sleep Res"},{"key":"10.1016\/j.nurt.2007.12.001_bib76","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/mds.20412","article-title":"Driving in Parkinson\u2019s disease: mobility, accidents, and sudden onset of sleep at the wheel","volume":"20","author":"Meindorfner","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib77","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.287.4.455","article-title":"Excessive daytime sleepiness and sudden-onset sleep in Parkinson\u2019s disease: a survey of the Canadian Movement Disorders Group","volume":"287","author":"Hobson","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.nurt.2007.12.001_bib78","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/archneur.62.8.1242","article-title":"Sudden uncontrollable somnolence and medication use in Parkinson disease","volume":"62","author":"Avorn","year":"2005","journal-title":"Arch Neurol"},{"issue":"Suppl 3","key":"10.1016\/j.nurt.2007.12.001_bib79","first-page":"S12","article-title":"Sleep issues in Parkinson\u2019s disease","volume":"64","author":"Adler","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib80","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF02938408","article-title":"Management of impulse control disorders in Parkinson\u2019s disease","volume":"9","author":"Galpern","year":"2007","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib81","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mds.10625","article-title":"Disabling repetitive behaviors in Parkinson\u2019s disease","volume":"19","author":"Kurlan","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib82","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0006-3223(94)90636-X","article-title":"Punding on levodopa","volume":"36","author":"Friedman","year":"1994","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.nurt.2007.12.001_bib83","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson\u2019s disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2007.12.001_bib84","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-198910000-00002","article-title":"Hypersexuality with antiparkinsonian therapy","volume":"12","author":"Uitti","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib85","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","article-title":"Prospective prevalence of pathologic gambling and medication association in Parkinson disease","volume":"66","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib86","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson\u2019s disease: a behavioral manifestation of pharmacologic treatment?","volume":"15","author":"Molina","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib87","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1212\/01.WNL.0000076478.45005.EC","article-title":"Pathological gambling associated with dopamine agonist therapy in Parkinson\u2019s disease","volume":"61","author":"Driver-Dunckley","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib88","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib89","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1212\/01.wnl.0000238503.20816.13","article-title":"Prevalence of repetitive and reward-seeking behaviors in Parkinson disease","volume":"67","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib90","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib91","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/mds.21072","article-title":"Prevalence of pathological gambling in patients with Parkinson\u2019s disease","volume":"21","author":"Avanzi","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib92","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/archneur.63.2.298-b","article-title":"Impulse control disorders and dopaminergic drugs","volume":"63","author":"Morgan","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib93","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/archneur.63.2.298-a","article-title":"Gambling and Parkinson disease","volume":"63","author":"Lu","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib94","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archneur.64.2.212","article-title":"Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease","volume":"64","author":"Voon","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib95","doi-asserted-by":"crossref","unstructured":"Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson\u2019s disease. Mov Disord 2007 Epub ahead of print; doi:10.1002\/mds.21770.","DOI":"10.1002\/mds.21770"},{"key":"10.1016\/j.nurt.2007.12.001_bib96","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00002826-200105000-00009","article-title":"Pathologic gambling in patients with Parkinson\u2019s disease","volume":"24","author":"Gschwandtner","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib97","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1212\/01.wnl.0000238401.76928.45","article-title":"Clinical features associated with impulse control disorders in Parkinson disease","volume":"67","author":"Pontone","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib98","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.parkreldis.2006.02.004","article-title":"Dopamine agonist therapy for Parkinson disease and pathological gambling","volume":"12","author":"Imamura","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib99","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/archneur.57.2.263","article-title":"Tasmar Advisory Panel","volume":"57","author":"Olanow","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/wnf.0b013e318038d2b6","article-title":"Tolcapone: an efficacy and safety review","volume":"30","author":"Olanow","year":"2007","journal-title":"Clin Neuropharmacol"},{"issue":"suppl 1","key":"10.1016\/j.nurt.2007.12.001_bib101","first-page":"S9","article-title":"COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons","volume":"21","author":"Jorga","year":"1998","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib102","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","article-title":"Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease","volume":"61","author":"Olanow","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib103","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.49.3.665","article-title":"Tolcapone Stable Study Group","volume":"49","author":"Waters","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib104","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.49.4.1066","article-title":"Tolcapone improves motor function in parkinsonian patients with the \u201cwearing-off\u201d phenomenon: a double-blind, placebo-controlled, multicenter trial","volume":"49","author":"Rajput","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib105","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jnnp.63.4.421","article-title":"Catechol-O-methyltransferase inhibition with tolcapone reduces the \u201cwearing off\u201d phenomenon and levodopa requirements in fluctuating parkinsonian patients","volume":"63","author":"Baas","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2007.12.001_bib106","first-page":"747","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson\u2019s disease patients [Erratum in: Ann Neurol 1998;44:292]","volume":"42","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib107","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.nurt.2007.12.001_bib108","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00002826-200109000-00007","article-title":"Long-term comparative experience with tolcapone and entacapone in advanced Parkinson\u2019s disease","volume":"24","author":"Factor","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib109","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mds.21131","article-title":"Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson\u2019s disease","volume":"22","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib110","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/mds.10342","article-title":"Entacapone-induced hepatotoxicity and hepatic dysfunction","volume":"17","author":"Fisher","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib111","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/WNF.0b013e318149f290","article-title":"Results from a 2-year centralized tolcapone liver enzyme monitoring program","volume":"30","author":"Lew","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib112","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/jnnp.2006.097154","article-title":"Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson\u2019s disease","volume":"78","author":"Lees","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2007.12.001_bib113","series-title":"Parkinson\u2019s disease: diagnosis and clinical management","first-page":"499","article-title":"Monoamine oxidase inhibitors","author":"Rajput","year":"2008"},{"key":"10.1016\/j.nurt.2007.12.001_bib114","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1126\/science.3875898","article-title":"Distinct monoamine oxidase A and B populations in primate brain","volume":"230","author":"Westlund","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.nurt.2007.12.001_bib115","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","article-title":"Effect of deprenyl on the progression of disability in early Parkinson\u2019s disease","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.12.001_bib116","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","article-title":"Effects of tocopherol and deprenyl on the progression of disability in early Parkinson\u2019s disease","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2007.12.001_bib117","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00002826-198810000-00001","article-title":"Deprenyl as symptomatic therapy in Parkinson\u2019s disease","volume":"11","author":"Golbe","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib118","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00002826-198802000-00004","article-title":"Deprenyl in the treatment of symptom fluctuations in advanced Parkinson\u2019s disease","volume":"11","author":"Golbe","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/syn.890180203","article-title":"Slow recovery of human brain MAO B after l-deprenyl (Selegeline) withdrawal","volume":"18","author":"Fowler","year":"1994","journal-title":"Synapse"},{"issue":"Suppl 4","key":"10.1016\/j.nurt.2007.12.001_bib120","first-page":"S80","article-title":"Clinical trials with rasagiline: evidence for short-term and long-term effects","volume":"66","author":"Siderowf","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib121","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.2042-7158.1998.tb06876.x","article-title":"Drug-delivery products and the Zydis fast-dissolving dosage form","volume":"50","author":"Seager","year":"1998","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib122","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00702-003-0036-4","article-title":"A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition","volume":"110","author":"Clarke","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.nurt.2007.12.001_bib123","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mds.20036","article-title":"Zydis selegiline reduces off time in Parkinson\u2019s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study","volume":"19","author":"Waters","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib124","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WNF.0b013e3180616570","article-title":"Selegiline orally disintegrating tablets in patients with Parkinson disease and \u201cwearing off\u201d symptoms","volume":"30","author":"Ondo","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2007.12.001_bib125","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1592\/phco.24.14.1295.43156","article-title":"Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor","volume":"24","author":"Thebault","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.nurt.2007.12.001_bib126","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study","volume":"59","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib127","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","article-title":"A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease","volume":"61","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study","volume":"62","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib129","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/mds.21048","article-title":"Effects of tyramine administration in Parkinson\u2019s disease patients treated with selective MAO-B inhibitor rasagiline","volume":"21","author":"deMarcaida","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib130","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00702-003-0042-6","article-title":"A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition","volume":"110","author":"Clarke","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.nurt.2007.12.001_bib131","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.45.2.219","article-title":"Serotonin syndrome","volume":"45","author":"Bodner","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib132","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.nurt.2007.12.001_bib133","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","article-title":"Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson\u2019s disease","volume":"48","author":"Richard","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib134","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","article-title":"Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"66","author":"Pahwa","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib135","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ncpneuro0340","article-title":"Drug insight: new drugs in development for Parkinson\u2019s disease","volume":"2","author":"Colosimo","year":"2006","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib136","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","article-title":"Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease","volume":"68","author":"Pahwa","year":"2007","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1016\/j.nurt.2007.12.001_bib137","first-page":"S30","article-title":"New pharmacologic horizons in the treatment of Parkinson disease","volume":"67","author":"Bonuccelli","year":"2006","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1016\/j.nurt.2007.12.001_bib138","first-page":"S24","article-title":"Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition","volume":"67","author":"Stocchi","year":"2006","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1016\/j.nurt.2007.12.001_bib139","first-page":"S18","article-title":"Safinamide: from molecular targets to a new anti-Parkinson drug","volume":"67","author":"Caccia","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/mds.870080208","article-title":"Subcutaneous apomorphine in Parkinson\u2019s disease: response to chronic administration for up to five years","volume":"8","author":"Hughes","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib141","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1034\/j.1600-0404.2001.00153.x","article-title":"Duodenal levodopa infusion in Parkinson\u2019s disease: long-term experience","volume":"104","author":"Nilsson","year":"2001","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nurt.2007.12.001_bib142","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson\u2019s disease","volume":"184","author":"Bibbiani","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib143","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib144","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mds.10464","article-title":"Fipamezole (JP-1730) is a potent \u03b12 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson\u2019s disease","volume":"18","author":"Savola","year":"2003","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2007.12.001_bib145","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.55.8.1089","article-title":"Tolcapone Fluctuator Study Group III","volume":"55","author":"Adler","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib146","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1468-1331.1997.tb00358.x","article-title":"Tolcapone International Parkinson\u2019s Disease Study (TIPS) Group I","volume":"4","author":"Myllyl\u00e4","year":"1997","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nurt.2007.12.001_bib147","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.48.1.81","article-title":"Tolcapone Fluctuator Study Group I","volume":"48","author":"Kurth","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib148","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Nomecomt Study Group","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2007.12.001_bib149","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00702-002-0799-z","article-title":"Efficacy and tolerability of entacapone in patients with Parkinson\u2019s disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations: a randomized, double-blind, multicentre study","volume":"110","author":"F\u00e9nelon","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.nurt.2007.12.001_bib150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":"Celomen Study Group","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurol Scand"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923005524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923005524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2007.12.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:42:31Z","timestamp":1761806551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923005524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S1878747923005524"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2007.12.001","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Status of Symptomatic Medical Therapy in Parkinson\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2007.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}